The use of Replicine™ Functional Keratin® to advance wound care in conditions ranging from Epidermolysis Bullosa to chronic wound care and acceleration of healing of complex wounds will be presented at EWMA, London, May 13-15.
Keraplast products have regulatory approval and reimbursement status in an increasing number of European countries. Keraplast is looking forward to this opportunity to introduce the Replicine™ Functional Keratin® product range to innovative clinicians, and work with a rapidly expanding group of distribution partners in Europe.
Please join us at the forefront of wound care at booth 1-68 of EWMA http://www.ewma2015.org/.
An evaluation of a keratin gel to accelerate healing and improve care for dystrophic epidermolysis bullosa patients, G Tadini, MD, U.O.S. Dermatologia Pediatrica – Dipartimento di Medicina Interna e Specializzazioni Mediche, IRCCS Ospedale Maggiore, Milano, Italy.
A clinical trial of a keratin gel to accelerate healing and improve comfort post haemorrhoidectomy, I Kolossa, MD, EBSQ, Intus Digestive and Colorectal Care, Christchurch, New Zealand.
Keratin dressings in the management of epidermolysis bullosa, J Denyer, Great Ormond Street Hospital, London, United Kingdom.
Effectiveness of topical therapies based on keratin for pressure sore in spinal cord injury, M Belci, MD, T Simone, MD, PRM, R Singhal, MD, L Stephen, RN, National Spinal Injury Centre, Stoke Mandeville, United Kingdom, University of Roma Tor Vergata, Italy and Burwood Hospital Spinal Unit, Christchurch, New Zealand.
Novel use of a keratin gel to epithelise areas with delayed healing as part of a procedure for giant nevus. J Jutkiewicz-Sypniewska, MD, M Plewko, MD, Department of Paediatric Surgery, Children’s Hospital of Professor J. Bogdanowicz, Warsaw, Poland